A detailed history of Fulcrum Equity Management transactions in Abb Vie Inc. stock. As of the latest transaction made, Fulcrum Equity Management holds 7,205 shares of ABBV stock, worth $1.3 Million. This represents 1.24% of its overall portfolio holdings.

Number of Shares
7,205
Previous 8,067 10.69%
Holding current value
$1.3 Million
Previous $1.38 Million 2.82%
% of portfolio
1.24%
Previous 1.28%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 21, 2024

SELL
$163.84 - $199.33 $141,230 - $171,822
-862 Reduced 10.69%
7,205 $1.42 Million
Q2 2024

Jul 19, 2024

BUY
$154.79 - $180.76 $200,453 - $234,084
1,295 Added 19.12%
8,067 $1.38 Million
Q1 2024

Apr 24, 2024

BUY
$159.82 - $182.1 $297,265 - $338,706
1,860 Added 37.87%
6,772 $1.23 Million
Q4 2023

Jan 18, 2024

BUY
$137.6 - $154.97 $17,062 - $19,216
124 Added 2.59%
4,912 $761,000
Q3 2023

Nov 13, 2023

BUY
$133.59 - $154.65 $216,415 - $250,533
1,620 Added 51.14%
4,788 $713,000
Q2 2023

Jul 07, 2023

BUY
$132.51 - $164.9 $5,962 - $7,420
45 Added 1.44%
3,168 $426,000
Q1 2023

Apr 06, 2023

BUY
$144.61 - $166.54 $223,711 - $257,637
1,547 Added 98.16%
3,123 $497,000
Q4 2022

Jul 07, 2023

SELL
$138.31 - $165.87 $220,189 - $264,065
-1,592 Reduced 50.25%
1,576 $254,000
Q4 2022

Jan 10, 2023

BUY
$138.31 - $165.87 $217,976 - $261,411
1,576 New
1,576 $0
Q1 2022

Apr 15, 2022

SELL
$131.98 - $163.75 $310,416 - $385,140
-2,352 Closed
0 $0
Q4 2021

Jan 25, 2022

SELL
$107.43 - $135.93 $5,693 - $7,204
-53 Reduced 2.2%
2,352 $318,000
Q3 2021

Jan 25, 2022

BUY
$106.4 - $120.78 $2,128 - $2,415
20 Added 0.84%
2,405 $259,000
Q2 2021

Jul 15, 2021

BUY
$105.21 - $117.21 $20,095 - $22,387
191 Added 8.71%
2,385 $269,000
Q1 2021

Apr 05, 2021

BUY
$102.3 - $112.62 $16,674 - $18,357
163 Added 8.03%
2,194 $237,000
Q4 2020

Feb 22, 2021

BUY
$80.49 - $108.67 $163,475 - $220,708
2,031 New
2,031 $218,000
Q3 2020

Oct 27, 2020

SELL
$85.91 - $100.83 $342,866 - $402,412
-3,991 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$73.37 - $98.18 $53,633 - $71,769
731 Added 22.42%
3,991 $392,000
Q1 2020

Apr 01, 2020

SELL
$64.5 - $97.79 $104,683 - $158,713
-1,623 Reduced 33.24%
3,260 $248,000
Q4 2019

Feb 12, 2020

SELL
$72.13 - $90.25 $17,022 - $21,299
-236 Reduced 4.61%
4,883 $432,000
Q3 2019

Nov 05, 2019

BUY
$62.98 - $75.72 $12,092 - $14,538
192 Added 3.9%
5,119 $388,000
Q2 2019

Aug 12, 2019

BUY
$65.7 - $83.98 $88,957 - $113,708
1,354 Added 37.9%
4,927 $323,000
Q1 2019

May 03, 2019

BUY
$77.14 - $90.79 $2,468 - $2,905
32 Added 0.9%
3,573 $288,000
Q4 2018

Mar 05, 2019

BUY
$77.85 - $96.01 $275,666 - $339,971
3,541 New
3,541 $326,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Fulcrum Equity Management Portfolio

Follow Fulcrum Equity Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fulcrum Equity Management, based on Form 13F filings with the SEC.

News

Stay updated on Fulcrum Equity Management with notifications on news.